Kornimate/medical-research-clean huggingface dataset:
platelet-rich plasma in the treatment of intractable postherpetic neuralgia

Conditions: PHN - Post-Herpetic Neuritis

Summary: used ultrasound-guided platelet rich plasma nerve block to treat intractable postherpetic neuralgia.

postherpetic neuralgia (phn) is a kind of pain caused by varicella zoster virus invading the human body and infecting the corresponding ganglia. the affected ganglia are inflamed or even necrotic, affecting the nerve endings, the dorsal horn of the spinal cord and the sensory nerve tissues below, and the course of the disease is more than one month or more. most patients can avoid phn by timely and effective treatment in the acute herpes zoster period. however, some patients with intractable postherpetic neuralgia fail to receive timely and effective pain control treatment in the early stage of the disease, and the current commonly used clinical treatment methods often fail to achieve effective treatment results. such patients often have a long course of disease, which can last for three to five years or even longer, nerve damage is also more serious. long term pain has seriously affected the quality of life of such patients. therefore, how to quickly and effectively control pain has become the diagnosis and treatment goal of such patients with intractable post herpetic neuralgia. platelet rich plasma (prp) was widely used in muscle and bone repair due to its function of promoting tissue repair in the early stage. recently, it was found that prp can also promote nerve repair. therefore, in order to further explore the therapeutic effect of prp on refractory phn patients, our department used ultrasound-guided platelet rich plasma nerve block to treat intractable phn.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria of phn: have a history of acute herpes zoster, the pain lasts for more than half a year, and there is paroxysmal pain in the affected nerve distribution area; * preoperative visual analog scale (vas) score ≥ 5; * those who can cooperate with the treatment; * we agreed to inject platelet rich plasma into nerve block under the guidance of ultrasound, and signed the informed consent form. exclusion criteria: * systemic infection or puncture local infection; * serious disturbance of cardiovascular and cerebrovascular function; * abnormal bleeding and coagulation function or complicated with blood system diseases; * mental disorders; * severe dysfunction of important organs in the body

Keywords: platelet-rich plasma intractable postherpetic neuralgia
a study of incmga00012 in metastatic merkel cell carcinoma (pod1um-201)

Conditions: Metastatic Merkel Cell Carcinoma

Summary: the purpose of this study is to assess the clinical activity and safety of incmga00012 in participants with advanced/metastatic merkel cell carcinoma (mcc).


Eligibility criteria:
inclusion criteria: * signed informed consent. * diagnosis of mcc with distant metastatic disease or recurrent, advanced locoregional disease not amenable to surgery or radiation * eastern cooperative oncology group performance status of 0 to 1. * measurable disease according to recist v1.1. * availability of tumor tissue (fresh or archival) for central pathology review. * willingness to avoid pregnancy or fathering children based on protocol-defined criteria. exclusion criteria: * prior systemic therapy for mcc, including chemotherapy and prior pd-1 or pd-l1-directed therapy. * treatment with anticancer drugs or participation in another interventional clinical study within 21 days before the first administration of study drug. * has not recovered to ≤ grade 1 or baseline from toxic effects of prior therapy (with the exceptions for anemia not requiring transfusion support and any grade of alopecia) and/or complications from prior surgical intervention within 7 days before starting study treatment. * radiation therapy administered within 2 weeks of first dose of study treatment or radiation therapy to the thoracic region that is \> 30 gy within 6 months of the first dose of study treatment. * known central nervous system (cns) metastases and/or carcinomatous meningitis. * history of second malignancy within 3 years (with exceptions). * laboratory values outside the protocol-defined range at screening. * clinically significant pulmonary, cardiac, gastrointestinal or autoimmune disorders. * active bacterial, fungal, or viral infections, including hepatitis a, b, and c. * receipt of a live vaccine within 28 days of planned start of study therapy. * current use of protocol-defined prohibited medication. * known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids). * inability or unlikely, in the opinion of the investigator, to comply with the protocol requirements. * participant who is pregnant or breastfeeding.

Keywords: metastatic merkel cell carcinoma anti-pd-1 antibody immunoglobulin g4 (igg4) monoclonal antibody incmga00012
cera™ vsd occluder post market clinical follow-up

Conditions: Ventricular Septal Defect

Summary: the objective of this post-market registry is to assess the safety and performance of the lifetech cera™ vsd occluder in a real-world and on-label fashion.

the study intends to collect data from patients who have implanted with the device before 2022. the study is expected to completed by the end of 2024.

Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of ventricular septal defect (vsd) and implanted with the investigational device as per ifu instructions exclusion criteria: * patients did not conduct any follow up visit after hospital discharge.

Keywords: cera vsd occluder observational retrospective multi-center
intraumbilical misoprostol in retained placenta

Conditions: Retained Placenta

Summary: administration of intraumbilical misoprostol to women with retained placenta despite active management of third stage of labour reduces the need for manual removal of placenta and the amount of blood loss vaginally.

retained placenta (rp)is one of the complications of third stage of labour; it should be managed promptly as it may cause severe bleeding, infection, maternal morbidity and mortality .the current standard management of rp word wide, by manual removal aims to prevent these problems, but it is unsatisfactory method because it requires general anaesthesia in hospital, it is an invasive procedure with its own serious complications of bleeding, infection and genital tract injury. umbilical vein injection of misoprostol is a simple, safe method and could be performed at the place of delivery .

Eligibility criteria:
inclusion criteria: * women having singleton pregnancy * 28 weeks of gestation or more delivered vaginally * prolongation of the third stage of labour (more than 30 min) following active management of third stage of labour exclusion criteria: * who refused to participate in the trial * multiple pregnancies * previous caesarean section * haemodynamically unstable * severe anaemia (haemoglobin less than 8gm/dl) * chorioamnionitis

Keywords: intraumbilical misoprostol retained placenta active management of third stage of labour
selection of laryngeal mask airway in patients with slender somatotype

Conditions: Size of Laryngeal Mask Airway; Body Weight; Success Rate of First Attempt; Complication

Summary: the size selection of laryngeal mask airway classic is usually followed the manufacturer's recommendation based on the patient's ideal weight. but sometimes the patient is tall and slim, the actual weight is much less than the ideal weight. this phenomenon might affect the success rate of insertion. previous studies had demonstrated that the selection of laryngeal mask airway size based on ideal weight could improve the success rate of insertion; therefore, this study was designed to prove whether this conclusion also applies to the tall and thin patients.

one hundred and eighteen patients adult patients，actual body weight much less than ideal body weight will be assigned randomly to two groups (actual weight group or ideal weight group). size selection was guided by the recommendations of manufacturer, patients will be based on the actual body weight in actual weight group while ideal body weight in ideal weight group. the success rate of first attempt，number of adjustments, insertion time, ease of insertion, overall success rate, oropharyngeal leak pressure and fiberoptic view will be recorded and compared. the occurrences of respiratory complications such as sore throat, hoarseness, and dysphonia will be observed and recorded.

Eligibility criteria:
inclusion criteria: 1. adult patients undergo elective surgery of american society of anesthesiologists (asa) physical status 1-2, aged from 18 to 60; 2. patients' actual weight much less than ideal weight. exclusion criteria: 1. patients with gastroesophageal reflux disease; 2. patients with predicted difficult airway; 3. patients with preexisting airway diseases or significant upper airway infection.

Keywords: laryngeal mask airway body weight complication
family satisfaction in the intensive care unit - a multicentre assessment

Conditions: Critical Illness

Summary: the primary aim of the present study is to assess satisfaction in a large sample of next of kin in swiss-german icus. secondary aims are to test the hypothesis that family satisfaction is related to icu structure and process and to factors related to patients and next of kin. further, the hypothesis will be tested that proxy assessment is possible, i.e. next of kin rate satisfaction with care similar to patients.


Eligibility criteria:
inclusion criteria: * family members of patients staying for \> 48 hours in an icu exclusion criteria: * lack of consent, * insufficient knowledge of german language
exercise intervention in patients with nontuberculous mycobacterial pulmonary disease

Conditions: Nontuberculous Mycobacteria

Summary: the study goal is to develop exercise intervention methods to improve the prognosis and quality of life of patients with non-tuberculous mycobacterial lung disease and to confirm the effectiveness of exercise intervention. this prospective study is scheduled to be conducted as a pre-post single-arm feasibility trial, targeting a total of 50 subjects.

1. after confirming the intention to participate in the study for patients with non-tuberculous mycobacterial lung disease who meet the selection criteria, basic personal information and clinical history information are collected. 2. when three people are recruited, they are organized into one group and begin a four-week exercise program. a total of 17 groups will be recruited and 50 people will be registered, and within 1 week before and after the start of the exercise program, vo2 max, physical function (6mwt, 30s sit to stand, sppb, handgrip strength), baseline pft, laboratory test, quality of life test (qol) -b, cat) is performed. 3. once a week for 4 weeks, full-body strength training and aerobic exercise are performed for 60 minutes with an exercise expert (supervised exercise), and the remaining 6 days a week are home-based exercises, in which the subject exercises independently at home. write it down in participants exercise diary. 4. vo2 max, physical function (6mwt, 30s sit to stand, sppb, handgrip strength), pft, laboratory test, and quality of life test (qol-b, cat) are conducted again within one week before and after the exercise intervention is completed.

Eligibility criteria:
inclusion criteria: adults aged 19 to 80 years diagnosed with non-tuberculous mycobacterial lung disease according to the ats/idsa guideline, patients with respiratory symptoms (cough, phlegm, difficulty breathing, etc.) at the time of selection, patients who understand the purpose of the clinical study and voluntarily agree to participate in this clinical study exclusion criteria: patients diagnosed with cardiovascular disease (angina, hfref, arrhythmia, history of heart valve surgery, etc.), patients who have had massive hemoptysis within the last 3 months, patients who have difficulty moving freely due to musculoskeletal problems (osteoarthritis, intervertebral disc herniation, spinal stenosis, etc.), patients who cannot read the consent form (e.g. illiterate, foreigner, etc.)
strengthening primary healthcare delivery for diabetes and hypertension in eswatini

Conditions: Diabetes Mellitus; Hypertension

Summary: the who-pen@scale project is a three-arm cluster-randomized trial that is investigating the population-level effects of a healthcare reform in eswatini, which aims to strengthen primary care for diabetes and hypertension. prior to the reform, healthcare for diabetes and hypertension was mostly provided through physician-led teams in hospital outpatient departments. the healthcare reform aims to strengthen the provision of nurse-led care for diabetes and hypertension in primary healthcare facilities and community health worker-led care for these conditions in the facilities' catchment areas. the reform will broadly be guided by the world health organization's "package of essential noncommunicable disease interventions for primary health care in low-resource settings" (who-pen). the trial will take place at 84 clusters (a primary healthcare facility and its catchment area) across the country.


Eligibility criteria:
inclusion criteria for the outcome assessment (household survey): * residing in one of the selected households * age ≥40 years exclusion criteria for the outcome assessment (household survey): * pregnant * inability to provide written informed consent

Keywords: diabetes mellitus diabetes hypertension who-pen health service decentralization community health worker eswatini swaziland scale-up implementation research cost-effectiveness mixed methods comorbidity non-communicable disease cardiovascular disease risk factors
mri and biomarkers for lung nodules detected during lung cancer screening

Conditions: Lung Cancer

Summary: the primary objective of this pilot observational study is to evaluate the accrual and retention rate of a study population from a centralized lung cancer screening program to support mri and blood-based biomarker research for lung cancer screening.


Eligibility criteria:
inclusion criteria: * ability to read and understand informed consent * male or female adults who are at high risk for lung cancer and are enrolled in the centralized lung cancer screening program: based on uspstf guidelines: age 50-80 with 20 or greater pack-year smoking story who continue to smoke or quit within the past 15 years without sign or symptoms of lung cancer. or based on national comprehensive cancer network (nccn) guidelines but do not meet the uspstf guidelines, age 50-unlimited * found to have one or more lung nodules that is 6mm or greater on screening ldct exclusion criteria: * persons with an active diagnosis of cancer * persons with active signs or symptoms of lung cancer * persons with mechanically, magnetically, or electrically activated implants, such as cardiac pacemakers, neurostimulators, and infusion pumps. * persons with ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged. * persons who are pregnant, nursing, are implanted with intrauterine devices (iud's) that are not mr-compatible * persons unable to tolerate mri imaging secondary to an inability to lie supine or severe claustrophobia. * persons who are non-compliant with visit instructions, including inability to lie still, hold breath or follow procedure instructions
prospective study on the efficacy of exclusive odontological and medical treatment in chronic dental maxillary sinusitis

Conditions: Chronic Maxillary Sinusitis

Summary: the study will be offered to patients for whom chronic maxillary sinusitis will be diagnosed in the first ent (ear, nose and throat) consultation. these patients will then be seen in a stomatology consultation to determine whether or not a dental cause is objective

chronic maxillary sinusitis is an inflammatory condition and/or infectious diseases of the maxillary sinus, which last longer than 12 weeks. those whose the origin is dental, are well described, and yet under-diagnosed most of the time due to a lack of well-defined diagnostic criteria and literature. there is controversy in the various studies about their prevalence. their management and in particular the therapeutic sequence, is not the subject of any recommendation and involves only a few clinical studies. their consequences on the patient's general health and quality of life are important. the lack of knowledge about them often leads to diagnostic errors and therefore to a persistence of symptomatology. moreover, their complications when they are not or incorrectly treated, although rare, can be dramatic (occulo-orbital or endo-cranial complications for example). preliminary work in the form of a retrospective study was carried out within of the centre hospitalier intercommunal de créteil in 2015. in view of the results the investigators wanted to set up a clinical trial with the following objectives measure the prevalence of chronic maxillary sinusitis of dental origin and measure the effectiveness of exclusive dental and medical treatment, which could avoid surgical intervention under general anaesthesia, at the higher morbidity.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. signed informed consent 3. patient with chronic maxillary sinusitis diagnosed by examination of the patient and ent examination by naso-fibroscopy 4. sinus imaging to confirm the diagnosis (facial mass scanner or cone beam ct) 5. affiliated or beneficiary of a social security scheme exclusion criteria: 1. fungal bullet sinusitis 2. naso-sinus polyposis 3. atelectasic sinusitis 4. systemic damage that may affect the maxillary sinuses (muciviscidosis, primary ciliary dyskinesia, vasculitis, granulomatosis, history of radiotherapy of the facial mass, pregnancy) 5. long-term immunosuppressive treatment (chemo, anti-rejection) 6. rhinosinusian tumor process 7. fronto-ethmoidomaxillary sinusitis with risk of orbital or meningeal damage in the short to medium term. 8. refusal of consent 9. simultaneous participation in another intervention research 10. patient under guardianship, curatorship or justice protection
study of biologic materials from the mediastinal lymph nodes from patients with lung disease.

Conditions: Lung Disease; Inflammation; Lung Cancer; Sarcoidosis

Summary: the purpose of this protocol is to obtain biologic materials from the mediastinal lymph nodes from patients with lung disease and mediastinal lymph node involvement in order to: (1) develop a better understanding of the cause and development of lung disorders involving the mediastinal lymph nodes; (2) identify biologic parameters that help diagnose and predict the behavior of human lung diseases; and (3) identify individuals who will be suitable candidates for other protocols such as those involving investigational new drugs.

this study will use bronchoscopy with endobronchial ultrasound-guided transbronchial needle aspiration (ebus-tbna) as part of their diagnostic work up as recommended by the treating physician. the procedure will be performed as standard of care, either under general anesthesia in the operating room or in the bronchoscopy suite under moderate sedation and analgesia. bronchoscopy with ebus-tbna is normally an ambulatory procedure. during the procedure, biopsy needle will be passed through the tube and a small sample will be taken for both diagnostic and research purposes. samples collected for diagnostic purposes will be sent to the department of pathology. additional biopsy samples will be collected for research purposes. the subject is observed after the bronchoscopy, including vital signs and level of consciousness, until they are back to baseline. all subjects will be discharged with an escort as per hospital policy. an overnight stay would be required for ambulatory individuals only if the individual is not, in the judgment of the treating attending physician, safe to be discharged as is standard practice.

Eligibility criteria:
inclusion criteria: * must provide informed consent * males and females, age 18 years and older * lung disease proven by at least one of the following: 1. symptoms consistent with pulmonary disease 2. chest x-ray and chest ct and/or pet ct scan consistent with lung disease and mediastinal lymph node involvement 3. lung biopsy consistent with lung disease known to involve mediastinal lymph nodes 4. patients with diseases of organs with known association to lung disease and mediastinal lymph node involvement. * undergoing fiberoptic bronchoscopy with ebus-tbna as dictated by their standard clinical care exclusion criteria: * patient refuses consent. * any history of allergies to xylocaine, lidocaine, versed, valium, atropine, or any local anesthetic will not be included in the study * individuals who cannot tolerate general anesthesia or moderate sedation and analgesia

Keywords: lung disease mediastinal lymph node bronchoscopy endobronchial-guided transbronchial needle aspiration
hydroxyzine for the prevention of pruritus from spinal morphine in transabdominal hysterectomy patients

Conditions: Pruritus; Nausea; Vomiting

Summary: hydroxyzine is one of antihistamines that antagonizes h1 receptor, and it's effects are reducing pruritus, nausea/vomiting, and the mild effect of sedation.with these effects hydroxyzine should be used in the prevention of these symptoms.

80 patients scheduled for elective transabdominal hysterectomy under combined spinal-general anesthesia. they were randomized to receive either hydroxyzine 75 mg and midazolam 7.5 mg (atr group) or placebo and midazolam 7.5 mg (control group) as premedication at least half an hour before operation. clinical data (vital signs, pruritic score, nauseous score, sedation score, etc) was recorded at preoperative, intraoperative and 48-hour postoperative periods. all patients had spinal block with 0.5% heavy bupivacaine 2 ml with 0.3 mg preservative free morphine and general anesthesia with thiopental sodium 250-300 mg as induction, intubated with atracurium 0.6 mg/kg and maintenance with nitrous oxide, oxygen and isoflurane. conventional reversal technique was done in all patients. fentanyl intravenous was used for pain as needed, chlopheniramine syrup 2 tsp (4mg/10 ml) every 4 hours was used for pruritus and ondansetron intravenous (8 mg) was used for nausea/vomiting in postoperative period. the results were reported in number of patients or percent of patients who were suffered from pruritus, nausea, vomiting or sedation.

Eligibility criteria:
inclusion criteria: * asa classification 1-2 * age from 18-60 years old * body mass index (bmi) below 35 * accepted combined spinal-general anesthesia exclusion criteria: * previous history of hydroxyzine allergy * underlying diseases of urticaria, pruritus, nausea vomiting and motion sickness * previous complications of procedure or anesthesia

Keywords: sedation